First-line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced NSCLC: 3-Year Update of CheckMate 227 Part 1

May 29-31, 2020; Online at meetings.asco.org/am
Chemotherapy-free treatment with first-line nivolumab and ipilimumab continues to provide durable clinical benefit to patients with advanced NSCLC, regardless of tumor PD-L1 expression.
Format: Microsoft PowerPoint (.ppt)
File Size: 361 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Downloadable slideset on the assessment of EGFR mutation and MET amplifications status in NSCLC, from Clinical Care Options (CCO)

Alexander Spira, MD, PhD, FACP Released: November 22, 2021

Downloadable slideset on the treatment of NSCLC harboring Exon 20 insertion mutations, from Clinical Care Options (CCO)

Enriqueta Felip, MD Released: November 22, 2021

Download this brief slideset on treatment options for advanced EGFR-mutated NSCLC that has progressed on first-line EGFR TKI therapy, from Clinical Care Options (CCO)

Helena A. Yu, MD Released: November 19, 2021

Download this brief slideset on resistance to EGFR TKI therapy in advanced EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Helena A. Yu, MD Released: November 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue